Bergman, Arthur
Pfizer (United States)
4 papers on CoChat
Most cited papers
- Verified
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
Calle, R. A., Amin, N. B., Carvajal-Gonzalez, S., Ross, T. T., Bergman, A., Aggarwal, S., Crowley, C., Rinaldi, A., Mancuso, J., Aggarwal, N., et al. (2021) · Nature Medicine
Liver Disease Diagnosis and TreatmentLipid metabolism and disorders
Cited by 219
- Verified
Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial
Saxena, A. R., Gorman, D. N., Esquejo, R. M., Bergman, A., Chidsey, K., Buckeridge, C., Griffith, D. A., & Kim, A. M. (2021) · Nature Medicine
Diabetes Treatment and ManagementPharmacology and Obesity Treatment
Cited by 156
- Verified
Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in Humans
Bergman, A. J., Murphy, G., Burke, J., Zhao, J. J., Valesky, R., Liu, L., Lasseter, K. C., He, W., Prueksaritanont, T., Qiu, Y., et al. (2004) · The Journal of Clinical Pharmacology
Lipoproteins and Cardiovascular HealthPharmacogenetics and Drug Metabolism
Cited by 97
- Verified
Effects of multiple ascending doses of the glucagon receptor antagonist PF ‐06291874 in patients with type 2 diabetes mellitus
Kazierad, D. J., Bergman, A., Tan, B., Erion, D. M., Somayaji, V., Lee, D. S., & Rolph, T. (2016) · Diabetes, Obesity and Metabolism
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 44
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free